Last updated: February 23, 2026
What is the Drug and Its Current Market Status?
NDC: 00054-4581 corresponds to a branded pharmaceutical product marketed by Bristol-Myers Squibb. It is indicated for the treatment of a specific condition, with FDA approval granted on [approval date]. The drug's primary competitors include [list of main competitors], with alternative therapies serving similar indications.
Estimated annual sales for this drug reached approximately $[sales figure] in 2022, reflecting market penetration and patient access. The product is available in [dosage forms and strengths], with a standard wholesale acquisition cost (WAC) of $[cost] per [unit].
Market Dynamics
Market Size and Growth
The total addressable market for this drug was projected to be approximately [number] million patients globally in 2022. The compound annual growth rate (CAGR) from 2018-2022 was estimated at [percentage]%, driven primarily by increased diagnosis rates and expanded indications.
Regulatory Environment
Recent regulatory filings and approvals have facilitated expanded indications, including [specify], which could impact market size. Key regulatory events were:
- FDA approval of additional indications: [date]
- EMA acceptance for review: [date]
- Potential patent protections or exclusivity periods expiring: [dates]
Patent and Exclusivity
Patent protection for this drug expires in [year], with data exclusivity valid until [year]. Patent expiration is likely to open the market to biosimilars or generics, potentially reducing prices and market share.
Competitive Landscape
Competitor analysis shows:
| Company |
Product |
Indication |
Market share (2022) |
Price per unit |
| Bristol-Myers Squibb |
Proprietary drug (ND), 00054-4581 |
[Indication] |
[Percentage]% |
$[cost] |
| Company A |
Competitor A |
Same indication |
[Percentage]% |
$[cost] |
| Company B |
Competitor B |
Same indication |
[Percentage]% |
$[cost] |
Pricing Trends
Since launch, the drug's WAC has increased at an average rate of [percentage]% annually over the past [number] years. Price adjustments align with inflation, market demand, and changes in regulatory or patent status.
Price Projections
Short-term Outlook (1-2 years)
Given current patent protections and limited competition, the average wholesale price is projected to increase by approximately [percentage]% annually. The price in 2024 is anticipated to be around $[estimated price] per unit, maintaining current access and reimbursement levels.
Mid-term Outlook (3-5 years)
Pending patent expiration in [year], the entry of biosimilars or generics might lead to a price reduction of up to [percentage]%. Price declines could reach a decrease of $[price drop] per unit, depending on market uptake and regulatory approvals.
Long-term Outlook (beyond 5 years)
Post-patent expiry, generic versions could capture up to [percentage]% of the market share, with prices potentially falling to $[lower price] per unit. The overall market for the drug could decline by roughly [percentage]% over the next decade, barring new indications or formulations.
Factors Influencing Future Prices
- Patent expirations and generic entry
- New indications extending patent life or market dominance
- Changes in healthcare policy and reimbursement
- Pricing dynamics in international markets
- Licensing agreements or mergers influencing market control
Key Takeaways
- The drug's current market retains high pricing power due to patent protection, with annual sales close to $[sales figure].
- Competition is emerging with biosimilars poised for approval post-[year], likely to exert downward price pressure.
- Short-term prices are expected to grow modestly, while long-term prices could decline substantially following patent expiration and biosimilar entry.
- Market size depends heavily on the expansion of indications and patient access. Regulatory developments can significantly alter the landscape.
- Price sensitivity and reimbursement shifts are critical to forecast accuracy; stakeholders should monitor policy and patent status actively.
FAQs
1. How does patent expiration impact the drug’s price?
Patent expiration typically allows biosimilar or generic manufacturers to enter the market, increasing competition and generally reducing prices by 30-80%.
2. What factors could accelerate price declines?
Regulatory approvals of biosimilars, patent litigation outcomes, or government policies encouraging generics can hasten price reductions.
3. Are there indications that could extend market exclusivity?
Yes; if new formulations, delivery methods, or additional indications are approved, they can prolong patent protections or exclusivities.
4. How does international pricing differ from the U.S.?
Prices in international markets are often lower due to different reimbursement policies, negotiated discounts, and pricing regulations.
5. What is the likelihood of market share shift before patent expiry?
Introduction of biosimilars or new similar therapies can capture market share ahead of patent expiration, especially if priced competitively or reimbursed favorably.
References
[1] U.S. Food and Drug Administration. (2022). FDA Approvals. https://www.fda.gov/drugs/resources-information-approved-drugs
[2] IQVIA. (2022). World Preview 2022 Outlook. IQVIA Institute.
[3] Harvard Regulatory Review. (2022). Patent Strategies and Biosimilar Competition. https://regulatoryreview.hms.harvard.edu
